Conferences and events

Learn about our upcoming conferences and access material from our past engagements. Please check back regularly for updates.

Future engagements

International Marketing and Advertising Law Forum – 3-5 December 2017, Frankfurt
Editorial versus marketing content: The shadow line between advertising and information”, moderated by Eveline Van Keymeulen 

Past engagements

French ePharma Day 2017 – 28 November 2017, Paris
“The new EU Clinical Trial Regulation: Preparing for implementation”, by Eveline Van Keymeulen and Marco de Morpurgo

Workshop “GMO Regulation – quo vadis?”, German Federal Office of Consumer Protection and Food Safety – 21 November 2017, Berlin
“Regulatory Requirements imposed by EU Primary Law”, by Tine Carmeliet

6th Annual Pharma Anti-Counterfeiting & Serialisation Conference – 18-20 September 2017, London
“Examining and complying with recent legislative and regulatory developments”, by Eveline Van Keymeulen

European Pharma Law Academy – 11-13 September 2017, Cambridge
“Biologics, Biosimilars and Biobetters – Regulation, Litigation, and Beyond”, by Marjan Noor and Rafi Allos
“Clinical Trials – Scope of the Regulation and preparing for implementation”, by Eveline Van Keymeulen and Marco de Morpurgo

BIO International Convention – 19-22 June, San Diego
“Brexit: What Might it Mean for Patent Prosecution, Litigation and Transactions in Europe?”, by Marc Döring

Life Sciences Intellectual Property Review’s Life Sciences Patent Network, North America – 1 June 2017, Boston
“Brexit and the future European patent landscape”, by Nicola Dagg
“The rise and rise of CRISPR Technology”, moderated by Frits Gerritzen
“Life Sciences Patents Open Table: Solving in-house counsel challenges”, by Nicola Dagg and Frits Gerritzen

C5’s 9th Forum on Pharma & Biotech Patent Litigation – 25-26 April 2017, Amsterdam
“What You Must Incorporate in Your Patent Claims”, by Marjan Noor

French ePharma Day 2016 – 30 November 2016, Paris
“Legal and Regulatory Challenges Related to Patient-Centricity in Drug Development: How Far Can Companies Go?”, by Eveline Van Keymeulen and Marco de Morpurgo

UK ePharma Day 2016 – 17 October 2016, London
“Legal and Regulatory Challenges Related to Patient-Centricity in Drug Development: How Far Can Companies Go?”, by Marco de Morpurgo and Steven Rix

C5 EU Pharmaceutical Regulatory Law – 27 September 2016, London
“What Companies Need to Know about the Bolar Exemption”, by Nicola Dagg and Jin Ooi

Les Matinées Life Sciences – 1st edition –  30 June 2016, Paris
“3D in Healthcare: A New Era of Personalised Medicine”, by Alexandre Rudoni, Eveline Van Keymeulen, Marco de Morpurgo and Audrey Aboukrat

IE University – 12 April 2016, Madrid
“Transparency of Clinical Trial Data in the EU: Striking a Balance between Pharmaceutical Innovation and Public Health”, by Marco de Morpurgo

24th Annual Fordham Intellectual Property Law & Policy Conference – 31 March 2016, New York
“Pharma, IP & Competition: EU developments”, by David Por

Future of Innovation in Medicine: Incentives for New Medical Treatments and Global Health – 3-4 December 2015, Seattle
“Challenges in Incentivizing Development of New Treatments and Drugs”, by Laëtitia Bénard
“Drug Development and Approval Process with its Part in Exclusivity”, moderated by Jin Ooi
“Patentability and Patent Extension of New Use and New Dosage Regimen for Existing Drugs”, by Jin Ooi

14th Pharmaceutical Patent Term Extensions Forum – 23 June 2015, Munich
“Supplementary Protection Certificates for second medical use patents and on side Products: Where do we stand?”, by Laëtitia Bénard

FT Digital Health Summit Europe – 10 June 2015, London
“Regulation Panel: Avoiding the regulatory pitfalls when it comes to digital transformation”, by Alexandre Rudoni

EU Pharmaceutical Law Forum – 20 May 2015, Brussels
“Second medical use claims”, by Laëtitia Bénard
“Examining unlicensed and off-label use”, by Eveline Van Keymeulen

Matinale SEPHIRE – 24 April 2015, Tunis
“Un regard international sur les relations entre l’industrie pharmaceutique et les professionnels de santé”, by Eveline Van Keymeulen

HEC Paris – 31 March 2015, Paris
“Lobbying in Brussels”, by Marco de Morpurgo

Pharmaceutical Regulatory and Legal Affairs Conference – 12 February 2015, Moscow
“Getting ready for ‘Sunshine’ in Russia: Lessons learned from the French Sunshine Act”, by Eveline Van Keymeulen

Drug Information Association (DIA) EuroMeeting – 26 March 2014, Vienna
“Early access to medicines: A comparison between national practices regarding off-label use (Making the patchwork more transparent)”, by Eveline Van Keymeulen

SciencesPo – 11 March 2014, Paris
“Regulation of Food Labeling and Advertising in the EU: Theory and Practice”, by Marco de Morpurgo